TY - JOUR
T1 - Acute endothelin-receptor inhibition does not attenuate acetylcholine- induced coronary vasoconstriction in experimental hypercholesterolemia
AU - Hasdai, David
AU - Best, Patricia J.M.
AU - Cannan, Charles R.
AU - Mathew, Verghese
AU - Schwartz, Robert S.
AU - Holmes, David R.
AU - Lerman, Amir
PY - 1998
Y1 - 1998
N2 - Endothelin (ET) may mediate the enhanced coronary vasoconstriction associated with hypercholesterolemia. We hypothesized that short-term inhibition of ET receptors attenuates the coronary epicardial vasoconstrictor response to acetylcholine in experimental hypercholesterolemia. ET-1 (group I, n=5; 5 ng · kg-1 · min-1) and acetylcholine (group III, n=7; 10-6 to 10-4 mol/L) were given by intracoronary infusion in pigs. ET-1 and acetylcholine were also infused with the specific ETA-receptor blocker FR- 139317 (5 μg · kg-1 · min-1; group II, n=6; group IV, n=6). Acetylcholine was also infused with the combined ET-receptor blocker, bosentan (0.5 mg/kg plus 1 mg · kg-1 · h-1, group V, n=5). The ETB- receptor agonist sarafotoxin 6c (5 ng · kg-1 · min-1; n=4) was also infused. The percentage change in coronary artery diameter (%ΔCAD) to the infusions was measured at baseline and after 10 weeks of high-cholesterol diet in all animals. Sarafotoxin 6c mildly reduced %ΔCAD at baseline and 10 weeks (-10 ± 2% and -12 ± 3%, respectively). FR-139317 did not attenuate the epicardial vasoconstrictor response to ET-1 at baseline (%ΔCAD -18 ± 8% for group I versus -12 ± 6% for group II; P=NS) but did at 10 weeks (%ΔCAD -77 ± 14% for group I versus -14 ± 6% for group II; P<.05). FR-139317 did not affect the response to acetylcholine at baseline (%ΔCAD 5 ± 2% for group III versus 7 ± 3% for group IV, P=NS) or at 10 weeks (%ΔCAD -23 ± 12% for group III versus -19 ± 7% for group IV; P=NS). Bosentan did not affect the response to acetylcholine at baseline or 10 weeks. Short-term ET- receptor inhibition in experimental hypercholesterolemia attenuated the enhanced coronary epicardial vasoconstrictor effects of ET-1 but not acetylcholine-induced coronary epicardial vasoconstriction, suggesting that acetylcholine-induced coronary epicardial vasoconstriction may not be mediated by ET receptors.
AB - Endothelin (ET) may mediate the enhanced coronary vasoconstriction associated with hypercholesterolemia. We hypothesized that short-term inhibition of ET receptors attenuates the coronary epicardial vasoconstrictor response to acetylcholine in experimental hypercholesterolemia. ET-1 (group I, n=5; 5 ng · kg-1 · min-1) and acetylcholine (group III, n=7; 10-6 to 10-4 mol/L) were given by intracoronary infusion in pigs. ET-1 and acetylcholine were also infused with the specific ETA-receptor blocker FR- 139317 (5 μg · kg-1 · min-1; group II, n=6; group IV, n=6). Acetylcholine was also infused with the combined ET-receptor blocker, bosentan (0.5 mg/kg plus 1 mg · kg-1 · h-1, group V, n=5). The ETB- receptor agonist sarafotoxin 6c (5 ng · kg-1 · min-1; n=4) was also infused. The percentage change in coronary artery diameter (%ΔCAD) to the infusions was measured at baseline and after 10 weeks of high-cholesterol diet in all animals. Sarafotoxin 6c mildly reduced %ΔCAD at baseline and 10 weeks (-10 ± 2% and -12 ± 3%, respectively). FR-139317 did not attenuate the epicardial vasoconstrictor response to ET-1 at baseline (%ΔCAD -18 ± 8% for group I versus -12 ± 6% for group II; P=NS) but did at 10 weeks (%ΔCAD -77 ± 14% for group I versus -14 ± 6% for group II; P<.05). FR-139317 did not affect the response to acetylcholine at baseline (%ΔCAD 5 ± 2% for group III versus 7 ± 3% for group IV, P=NS) or at 10 weeks (%ΔCAD -23 ± 12% for group III versus -19 ± 7% for group IV; P=NS). Bosentan did not affect the response to acetylcholine at baseline or 10 weeks. Short-term ET- receptor inhibition in experimental hypercholesterolemia attenuated the enhanced coronary epicardial vasoconstrictor effects of ET-1 but not acetylcholine-induced coronary epicardial vasoconstriction, suggesting that acetylcholine-induced coronary epicardial vasoconstriction may not be mediated by ET receptors.
KW - Acetylcholine
KW - Endothelin
KW - Endothelin receptor
KW - Hypercholesterolemia
KW - Pig
UR - http://www.scopus.com/inward/record.url?scp=0031984704&partnerID=8YFLogxK
U2 - 10.1161/01.ATV.18.1.108
DO - 10.1161/01.ATV.18.1.108
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 9445263
AN - SCOPUS:0031984704
SN - 1079-5642
VL - 18
SP - 108
EP - 113
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
IS - 1
ER -